Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy.

Date publication

août 2012

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc , Dr FAGNONI Philippe , Pr NERICH Virginie , Pr PIVOT Xavier

Tous les auteurs :
Chaumard N, Limat S, Villanueva C, Nerich V, Fagnoni P, Bazan F, Chaigneau L, Dobi E, Cals L, Pivot X

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22123411

Résumé

BACKGROUND: The study's objective was to assess the predictive factors of anemia induced by chemotherapy in early breast cancer patients. PATIENTS AND METHODS: Patients treated by adjuvant or neo-adjuvant anthracyclin-based regimens with or without taxanes between 1998 and 2006 in a French university hospital were studied. Chemotherapy included. Anemia was defined as a hemoglobin (Hb) concentration lower than 12 g/dL. Multivariate analysis by logistic regression was used to search for baseline risk factors linked to the occurrence of anemia. RESULTS: Among 378 patients, anemia was observed in 64% of cases. The occurrence of anemia was significantly related to 6 risk factors: exposure to taxanes (HR 11.5, 95% CI, 2.5-52.6), high dose of anthracyclin (epirubicin 100 mg/m(2))(HR 4.3; 95% CI, 2.8-8), Hb at baseline < 13.5 g/d (HR 4.3; 95% CI, 2.6-7.1), mastectomy (HR 2.5; 95% CI, 1.4-3.3), age >60 (HR 2.5; 95% CI, 1.4-5) years old (HR 2.5; 95% CI, 1.4-5) and Body Mass Index (BMI)

Référence

Breast. 2012 Aug;21(4):464-7